Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets.

Müller AMS, Min D, Wernig G, Levy RB, Perez VL, Herretes S, Florek M, Burnett C, Weinberg K, Shizuru JA.

Biol Blood Marrow Transplant. 2019 Aug 12. pii: S1083-8791(19)30515-4. doi: 10.1016/j.bbmt.2019.08.001. [Epub ahead of print]

PMID:
31415899
2.

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.

Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ.

Nat Commun. 2019 Feb 6;10(1):617. doi: 10.1038/s41467-018-08201-x.

3.

Doxycycline Reduces Scar Thickness and Improves Collagen Architecture.

Moore AL, desJardins-Park HE, Duoto BA, Mascharak S, Murphy MP, Irizarry DM, Foster DS, Jones RE, Barnes LA, Marshall CD, Ransom RC, Wernig G, Longaker MT.

Ann Surg. 2018 Dec 21. doi: 10.1097/SLA.0000000000003172. [Epub ahead of print]

PMID:
30585822
4.

Surgical adhesions in mice are derived from mesothelial cells and can be targeted by antibodies against mesothelial markers.

Tsai JM, Sinha R, Seita J, Fernhoff N, Christ S, Koopmans T, Krampitz GW, McKenna KM, Xing L, Sandholzer M, Sales JH, Shoham M, McCracken M, Joubert LM, Gordon SR, Poux N, Wernig G, Norton JA, Weissman IL, Rinkevich Y.

Sci Transl Med. 2018 Nov 28;10(469). pii: eaan6735. doi: 10.1126/scitranslmed.aan6735.

PMID:
30487249
5.

Direct targeting of the mouse optic nerve for therapeutic delivery.

Mesentier-Louro LA, Dodd R, Domizi P, Nobuta H, Wernig M, Wernig G, Liao YJ.

J Neurosci Methods. 2019 Feb 1;313:1-5. doi: 10.1016/j.jneumeth.2018.10.038. Epub 2018 Oct 31.

PMID:
30389488
6.

Unifying mechanism for different fibrotic diseases.

Wernig G, Chen SY, Cui L, Van Neste C, Tsai JM, Kambham N, Vogel H, Natkunam Y, Gilliland DG, Nolan G, Weissman IL.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4757-4762. doi: 10.1073/pnas.1621375114. Epub 2017 Apr 19.

7.

Mapping the Pairwise Choices Leading from Pluripotency to Human Bone, Heart, and Other Mesoderm Cell Types.

Loh KM, Chen A, Koh PW, Deng TZ, Sinha R, Tsai JM, Barkal AA, Shen KY, Jain R, Morganti RM, Shyh-Chang N, Fernhoff NB, George BM, Wernig G, Salomon REA, Chen Z, Vogel H, Epstein JA, Kundaje A, Talbot WS, Beachy PA, Ang LT, Weissman IL.

Cell. 2016 Jul 14;166(2):451-467. doi: 10.1016/j.cell.2016.06.011.

8.

Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.

Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary P, Majeti R, Constantinescu SN, Piehler J, Garcia KC.

Cell. 2015 Mar 12;160(6):1196-208. doi: 10.1016/j.cell.2015.02.011. Epub 2015 Feb 26.

9.

STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante SV, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, Robinson GW, Hennighausen L, Gilliland DG, Kindler T.

Cancer Res. 2013 Jan 1;73(1):373-84. doi: 10.1158/0008-5472.CAN-12-0255. Epub 2012 Nov 13.

10.

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.

Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL.

Leukemia. 2012 Dec;26(12):2538-45. doi: 10.1038/leu.2012.141. Epub 2012 May 30.

PMID:
22648449
11.

EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.

Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, Clary DO, Gilliland DG.

Leukemia. 2012 Apr;26(4):720-7. doi: 10.1038/leu.2011.261. Epub 2011 Oct 18.

PMID:
22005786
12.

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.

Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.

13.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG.

Cancer Cell. 2008 Apr;13(4):311-20. doi: 10.1016/j.ccr.2008.02.009.

14.

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ.

Blood. 2008 May 1;111(9):4788-96. doi: 10.1182/blood-2007-07-101394. Epub 2008 Feb 5.

15.

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.

16.

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.

PMID:
17124066
17.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

18.

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Fröhling S, Cullen D, Polakiewicz RD, Bernard OA, Boggon TJ, Lee BH, Gilliland DG.

Blood. 2006 Oct 15;108(8):2770-9. Epub 2006 Jun 27.

19.

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.

20.

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, Gilliland DG, Lodish H.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7. Epub 2005 Dec 19.

21.

The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment.

Wernig G, Janzen V, Schäfer R, Zweyer M, Knauf U, Hoegemeier O, Mundegar RR, Garbe S, Stier S, Franz T, Wernig M, Wernig A.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11852-7. Epub 2005 Aug 5.

22.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG.

Cancer Cell. 2005 Apr;7(4):387-97.

Supplemental Content

Loading ...
Support Center